Evidence map›Paper›PMID 29395184›Full record

ArticleThe Journal of pediatrics2018

Management of Hypertension and High Low-Density Lipoprotein in Pediatric Type 1 Diabetes.

Michelle L Katz, Zijing Guo, Lori M Laffel

Open access · greenAbstract read
In one paragraph

Article in The Journal of pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Adolescent and Parent Perceptions of Long-Term Type 1 Diabetes Complications.Diabetes spectrum : a publication of the American Diabetes Association · 2021
    Article
  7. Review
  8. Beneficial Effects of Physical Activity in Diabetic Patients.Journal of functional morphology and kinesiology · 2020
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michelle L KatzPediatric, Adolescent and Young Adult Section, Boston, MA; Section on Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Boston, MA. Electronic address: michelle.katz@joslin.harvard.edu.
Zijing GuoSection on Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Boston, MA.
Lori M LaffelPediatric, Adolescent and Young Adult Section, Boston, MA; Section on Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Boston, MA.
Joslin Diabetes Center · US

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
CAREER DEVELOPMENT IN DIABETES RESEARCH FOR PEDIATRIC ENDOCRINOLOGISTSK12DK094721 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI LAFFEL, LORI M, WHITE, MORRIS F. · 2011 to 2021
$6.3M
Improving Management Strategies for Blood Pressure and Lipids in Pediatric T1DK23HL125976 · NHLBI · JOSLIN DIABETES CENTER · PI KATZ, MICHELLE LYNNE · 2015 to 2017
$514k
NHLBI NIH HHS K23 HL125976NIDDK NIH HHS K12 DK094721NIDDK NIH HHS P30 DK036836
6 · The paper itself

Abstract

objectiveTo evaluate hypertension and hyperlipidemia management patterns in youth with type 1 diabetes and to assess perceived effectiveness of management strategies and barriers to management. STUDY

designAn electronic survey, including clinical scenarios, fielded to pediatric providers (members of the American Diabetes Association Diabetes in Youth Interest Group, Pediatric Endocrine Society, or T1D Exchange).

resultsRespondents (N = 207, 86% MDs, 68% female) were practicing clinicians for youth with type 1 diabetes. As an initial recommendation, the overwhelming majority of respondents (83%-99%) endorsed lifestyle and nonmedical recommendations (eg, improve glycemic control) for hypertension and hyperlipidemia. Yet, few (6%-17%) reported these recommendations as effective. Many respondents (57%) reported referring to another specialist for hypertension, whereas few (8%) reported referring to another specialist for hyperlipidemia management. Approximately one-fifth (21%) of respondents never initiate antihypertensive medications, whereas only 8% never initiate lipid-lowering medication. Among prescribers, the majority of respondents only started antihypertensive or lipid-lowering medications after persistent elevations and in the setting of either ineffective lifestyle or nonmedical interventions or additional cardiovascular risk factors. More than two-thirds of respondents endorsed medications as often effective for hypertension and hyperlipidemia (68% and 69%, respectively).

conclusionsPediatric diabetes providers commonly defer prescribing antihypertensive and lipid-lowering medications until nonmedication interventions have been ineffective. Most providers describe medications, but not lifestyle interventions, as often effective. Efforts to align clinical practice with clinical guidelines are needed.

Indexed as

AdultAgedAntihypertensive AgentsDiabetes Mellitus, Type 1FemaleHealthy LifestyleHumansHyperlipidemiasHypertensionHypolipidemic AgentsLipoproteins, LDLMaleMiddle AgedPractice Patterns, Physicians'Referral and ConsultationSurveys and QuestionnairesAntihypertensive AgentsHypolipidemic AgentsLipoproteins, LDLanti-hypertensivecholesterollipid-lowering

Identifiers

PMID29395184
PMCPMC6013061
OpenAlexW2793813081

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.